Rapid decreases of key antioxidant molecules in critically ill patients: A personalized approach

2020 ◽  
Vol 39 (4) ◽  
pp. 1146-1154 ◽  
Author(s):  
N.V. Margaritelis ◽  
V. Paschalis ◽  
A.A. Theodorou ◽  
V. Vassiliou ◽  
A. Kyparos ◽  
...  
2019 ◽  
Vol 40 (05) ◽  
pp. 571-579
Author(s):  
Mayanka Tickoo

AbstractIn the critically ill adult, dysglycemia is a marker of disease severity and is associated with worse clinical outcomes. Close monitoring of glucose and use of insulin in critically ill patients have been done for more than 2 decades, but the appropriate target glycemic range in critically ill patients remains controversial. Physiological stress response, levels of inflammatory cytokines, nutritional intake, and level of mobility affect glycemic control, and a more personalized approach to patients with dysglycemia is warranted in critically ill intensive care unit (ICU) patients. We discuss the pathophysiology and downstream effects of altered glycemic response in critical illness, management of glycemic control in the ICU, and future strategies toward personalization of critical care glycemic management.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Brandon Chan ◽  
Brian Chen ◽  
Alireza Sedghi ◽  
Philip Laird ◽  
David Maslove ◽  
...  

2021 ◽  
Vol 10 (24) ◽  
pp. 5815
Author(s):  
Ivo Udovicic ◽  
Ivan Stanojevic ◽  
Dragan Djordjevic ◽  
Snjezana Zeba ◽  
Goran Rondovic ◽  
...  

Immune cells and mediators play a crucial role in the critical care setting but are understudied. This review explores the concept of sepsis and/or injury-induced immunosuppression and immuno-inflammatory response in COVID-19 and reiterates the need for more accurate functional immunomonitoring of monocyte and neutrophil function in these critically ill patients. in addition, the feasibility of circulating and cell-surface immune biomarkers as predictors of infection and/or outcome in critically ill patients is explored. It is clear that, for critically ill, one size does not fit all and that immune phenotyping of critically ill patients may allow the development of a more personalized approach with tailored immunotherapy for the specific patient. In addition, at this point in time, caution is advised regarding the quality of evidence of some COVID-19 studies in the literature.


Sign in / Sign up

Export Citation Format

Share Document